Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
暂无分享,去创建一个
A Vergnenegre | X. Chen | X. Qian | M. Sánchez-Ronco | B. Massuti | M. Provencio | C. Camps | J. Wei | L. Yu | N. Karachaliou | M. Dómine | A. Vergnenègre | C. You | L. Wang | T. Morán | A. Insa | I. Bover | D. Isla | N. Baize | G. Robinet | G. López-Vivanco | A. Drozdowskyj | C Camps | Y. Song | M Provencio | T Moran | J Wei | M Cobo | X Qian | M Domine | Z Zou | I Bover | L Wang | L Yu | I Chaib | C You | B Massuti | Y Song | H Lu | G Lopez-Vivanco | W Hu | G Robinet | J Yan | A Insa | X Xu | M Majem | X Chen | R de Las Peñas | N Karachaliou | M A Sala | Q Wu | D Isla | Y Zhou | N Baize | F Zhang | J Garde | P Germonpre | S Rauh | H ALHusaini | M Sanchez-Ronco | A Drozdowskyj | J J Sanchez | B Liu | R Rosell | M. Majem | M. Cobo | B. Liu | P. Germonpré | R. Rosell | S. Rauh | H. Lu | R. de las Peñas | M. Sala | J. Garde | I. Chaib | Z. Zou | H. Alhusaini | Y. Zhou | F. Zhang | X. Xu | J. Sánchez | Q. Wu | J. Yan | W. Hu | B. Massutí | P. Germonpre
[1] P. Johnston,et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.
[2] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[3] R. Rosell,et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. , 2011, Journal of the National Cancer Institute.
[4] P. Johnston,et al. BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy , 2007, Clinical Cancer Research.
[5] R. Rosell,et al. Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression , 2009, PloS one.
[6] Steven P Gygi,et al. Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response , 2007, Science.
[7] Katherine S. Lovejoy,et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. , 2010, Genes & development.
[8] A. Ashworth,et al. The DNA damage response and cancer therapy , 2012, Nature.
[9] T. Ludwig,et al. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. , 2012, Molecular cell.
[10] D. Gandara,et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Rugge,et al. The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2013, Annals of Oncology.
[12] Michael Albers,et al. Ubiquitin-interaction motifs of RAP80 are critical in its regulation of estrogen receptor α , 2007, Nucleic acids research.
[13] G. Bepler,et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Rafael Rosell,et al. Genetics and biomarkers in personalisation of lung cancer treatment , 2013, The Lancet.
[15] K. Syrigos,et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Jos Jonkers,et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer , 2007, Proceedings of the National Academy of Sciences.
[17] K. Matsuo,et al. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. , 2012, Cancer research.
[18] Jeremy M. Stark,et al. 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks , 2010, Cell.
[19] M. Rugge,et al. The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy , 2013, Oncotarget.
[20] Baorui Liu,et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel , 2008, BMC Cancer.
[21] D. Mavroudis,et al. Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients , 2008, PloS one.